INmune Bio received written alignment from the UK MHRA on its 2026 plan to seek conditional marketing authorization for CORDStrom™ (Ebstrocel™) to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. MHRA agreed on the manufacturing, clinical, and non-clinical data requirements and recognized Phase 2 trial data showing meaningful symptom relief, especially for pain and itching, supporting its use as a chronic or intermittent therapy. The company is incorporating MHRA feedback into its Phase 3 trial design and aims to submit applications in the UK, EU, and US by late 2026 or early 2027. This regulatory milestone reduces risk and provides a clear path for potential approval of this novel cell therapy in an ultra-rare disease with limited treatment options.
A KAYAK survey of 2,000 Brazilian travelers revealed Cristiano Ronaldo as the most desired football companion for trips, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9%, respectively. The Northeast region of Brazil,...
A KAYAK survey of 2,000 Brazilian travelers found Cristiano Ronaldo is the most desired football player to travel with, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9% respectively. Most Brazilians (59%) would take ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Oryn Therapeutics is progressing its next-generation Orynotide™ macrocyclic peptide platform aimed at treating inflammatory and autoimmune diseases through immune reprogramming rather than suppression. The company appointed Guy Rosenthal as CEO and e...
Dimensional Fund Advisors Ltd. has disclosed a 1.41% ownership stake in Advanced Medical Solutions Group PLC, holding 3,110,204 ordinary shares as of June 22, 2026. This disclosure follows regulatory requirements under the Takeover Code, indicating D...
